Vext Science (CSE:VEXT) Full Year 2024 Results
Key Financial Results
- Revenue: US$36.0m (up 3.4% from FY 2023).
- Net loss: US$22.4m (down from US$4.40m profit in FY 2023).
- US$0.093 loss per share (down from US$0.027 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vext Science EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 44%.
Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are down 2.7% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Vext Science (2 don't sit too well with us!) that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Vext Science might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.